Spero Therapeutics, Inc.
SPRO
$2.33
$0.010.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.55M | 48.58M | 44.58M | 47.98M | 106.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.55M | 48.58M | 44.58M | 47.98M | 106.46M |
| Cost of Revenue | 125.39M | 143.65M | 156.71M | 160.43M | 117.36M |
| Gross Profit | -69.79M | -80.03M | -97.08M | -97.41M | -10.90M |
| SG&A Expenses | 23.93M | 24.96M | 24.61M | 23.70M | 23.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.64M | 104.93M | 117.64M | 120.46M | 107.56M |
| Operating Income | -45.09M | -56.36M | -73.06M | -72.48M | -1.10M |
| Income Before Tax | -43.55M | -53.60M | -69.76M | -68.57M | 3.61M |
| Income Tax Expenses | 290.00K | 0.00 | 0.00 | 0.00 | 97.00K |
| Earnings from Continuing Operations | -43.84 | -53.60 | -69.76 | -68.57 | 3.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.84M | -53.60M | -69.76M | -68.57M | 3.51M |
| EBIT | -45.09M | -56.36M | -73.06M | -72.48M | -1.10M |
| EBITDA | -45.09M | -56.36M | -73.06M | -72.39M | -973.30K |
| EPS Basic | -0.79 | -0.98 | -1.28 | -1.27 | 0.08 |
| Normalized Basic EPS | -0.47 | -0.60 | -0.79 | -0.78 | 0.05 |
| EPS Diluted | -0.80 | -0.98 | -1.28 | -1.27 | 0.08 |
| Normalized Diluted EPS | -0.47 | -0.60 | -0.79 | -0.78 | 0.05 |
| Average Basic Shares Outstanding | 222.22M | 220.07M | 218.00M | 216.15M | 214.61M |
| Average Diluted Shares Outstanding | 222.22M | 220.07M | 218.00M | 216.15M | 214.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |